Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Blood|June 5, 2008
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashionBrian Kavanagh, Shaun O'Brien, David Lee, et al.
Neuro-Oncology|June 4, 2011
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastomaBaisakhi Raychaudhuri, Patricia Rayman, Joanna Ireland, et al.
Targeted Oncology|August 11, 2021
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and NivolumabKunal Desai, Landon Brown, Wei Wei, et al.
Investigational New Drugs|April 7, 2010
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic diseaseRobert Dreicer, Jorge Garcia, Maha Hussain, et al.
Journal of Neurosurgery. Spine|July 9, 2016
Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinomaJacob A Miller, Ehsan H Balagamwala, Lilyana Angelov, et al.
Journal of Cancer Survivorship : Research and Practice|April 9, 2011
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinomaPeter C Trask, Andrew G Bushmakin, Joseph C Cappelleri, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 10, 2019
Descriptive comparison of hospital formulary decisions with published oncology valuation methodsSimon W Lam, Caitlin Siebenaller, Marc Earl, et al.
The American Journal of Surgical Pathology|October 31, 2008
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidenceMing Zhou, Eric Kort, Philip Hoekstra, et al.
Cancer Research|April 22, 2010
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrainedJennifer S Ko, Patricia Rayman, Joanna Ireland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patientsJames H Finke, Brian Rini, Joanna Ireland, et al.
Pageof 10